Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”

Conduit C, Mak B, Qu W, et al. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol). Ther Adv Med Oncol 2022; 14: 1–13. DOI: 10.1177/17588359221092486

In the above-referenced paper, there was a text error in Figure 1, which has now been corrected in the online version of the article. Patients with an undetectable mGSTP1 prior to commencing cycle 3 are eligible to consent to the main study, not those with a detectable mGSTP1 as previously stated.

Figure 1.

Study schema.